Trials
3 active
6 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose…”In the company’s words, NCT06438471 on ClinicalTrials.gov
- Tested for
- Parkinson's Disease (PD), Chronic Kidney Disease, Spinal Cord Injuries, Neuropathic Pain, Degenerative Disc Disease, Spinal Stenosis, Spondylosis
- Main trialPhase 1/2
- “The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are: * Is EC5026 safe in adults with Parkinson's Disease? * What are the levels of EC5026 achieved after oral administration for 28 days? * What molecules or pathways does EC5026 target, and to what extent? In addition, although it is not one of the primary aims of the…”In the company’s words, NCT07142044 on ClinicalTrials.gov
Other drugs for Chronic Kidney Disease
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
Coming up3
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2026 | Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study) | |
| Phase 1Recruiting | 31 Dec 2026 | Renal Impairment Study for Oral EC5026 | |
| Phase 1Recruiting | Dec 2027 | Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury | |
| Phase 1Completed | 7 Jul 2020 | Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects | |
| Phase 1Completed | 12 May 2021 | Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects | |
| Phase 1Completed | 13 Mar 2024 | Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026